Opioid Use Disorder Market Size in the 7MM was ~USD 2,000 Million in 2023, estimated DelveInsight

DelveInsight's "Opioid Use Disorder Market Insights, Epidemiology and Market Forecast - 2034" report delivers an in-depth understanding of Opioid Use Disorder, historical and forecasted epidemiology as well as the Opioid Use Disorder market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Discover Key Insights into the Opioid Use Disorder Market with DelveInsight's In-Depth Report @ Opioid Use Disorder Market Size [https://www.delveinsight.com/sample-request/opioid-use-disorder-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Opioid Use Disorder Market Report

* In November 2024:- Indivior Inc.- The purpose of this study is to measure safety and efficacy and to determine dose-response relationship for INDV-2000 in participants with moderate to severe Opioid Use Disorder (OUD) who are new to treatment, have recently initiated or completed short-term medically supervised withdrawal with transmucosal (TM) buprenorphine, and are interested in transitioning to a non opioid treatment.
* In November 2024:- NYU Langone Health- This is a two phase study investigating combinations of pharmacological and behavioral interventions to optimize the treatment of Opioid Use Disorder (OUD). The Retention Phase will assess strategies for improving retention on buprenorphine (BUP) and extended-release injectable naltrexone (XR-NTX). The Discontinuation Phase will assess which approaches are most likely to lead to long-term success (absence of relapse), and what characteristics of participants distinguish those who can safely discontinue Medications for Opioid Use Disorder (MOUD) from those who remain at risk of relapse and should not discontinue.
* As per DelveInsight's estimates, the total prevalent population of OUD in the US was more than 2,100,000 in 2023.
* Opioid Use Disorder (OUD) was more common in males compared to females across the 7MM.
* Most cases of OUD are found in the age group of 18 to 25 years, followed by 26 or older years.
* The prevalent population of OUD in EU4 and the UK was ~1,440,000 cases in 2023 and the highest prevalent population was accounted by Germany.
* The leading Opioid Use Disorder Companies such as Indivior PLC, Alkermes, Orexo AB, Titan Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., Mallinckrodt Pharmaceuticals, BioDelivery Sciences International Inc., Viatris Inc., Pfizer, Inc., Hikma Pharmaceuticals PLC, Camurus , and others
* Promising Opioid Use Disorder Therapies such as CAM2038, BXCL501, MN-166, AZD4041, CVL-354, INDV-2000, NYX-783 , and others

Stay ahead in the Opioid Use Disorder Therapeutics Market with DelveInsight's Strategic Report @ Opioid Use Disorder Market Outlook [https://www.delveinsight.com/sample-request/opioid-use-disorder-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Opioid Use Disorder Epidemiology Segmentation in the 7MM

* Total Opioid Use Disorder Prevalent Cases
* Opioid Use Disorder Gender-specific Cases
* Opioid Use Disorder Age-specific Cases
* Opioid Use Disorder Severity-specific Cases

Download the report to understand which factors are driving Opioid Use Disorder epidemiology trends @ Opioid Use Disorder Prevalence [https://www.delveinsight.com/sample-request/opioid-use-disorder-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Opioid Use Disorder Marketed Drugs

* BRIXADI (buprenorphine): Braeburn Pharmaceuticals

BRIXADI contains buprenorphine, a partial opioid agonist. It is prescribed for moderate to severe opioid addiction in individuals who have initiated treatment with buprenorphine or are already undergoing buprenorphine therapy. It's an integral part of a comprehensive treatment plan that includes counseling and behavioral therapy.

BRIXADI is approved in both weekly and monthly subcutaneous injectable formulations at varying doses, including lower doses that may be appropriate for those who do not tolerate higher doses of extended-release buprenorphine that are currently available. The weekly doses are 8 milligrams (mg), 16 mg, 24 mg, 32 mg; and the monthly doses are 64 mg, 96 mg, and 128 mg.

* SUBLOCADE (buprenorphine): Indivior

SUBLOCADE, a partial opioid agonist, and is indicated for the treatment of moderate to severe opioid use disorder in patients who have initiated treatment with a transmucosal buprenorphinecontaining product, followed by dose adjustment for a minimum of 7 days. SUBLOCADE should be part of a complete treatment program that includes counseling and psychosocial support.

Opioid Use Disorder Emerging Drugs

* BXCL501: BioXcel Therapeutics

BXCL501 is an investigational, proprietary, orally dissolving thin film formulation of dexmedetomidine, a selective alpha-2a receptor agonist for the treatment of agitation and opioid withdrawal symptoms. BioXcel believes that BXCL501 potentially targets a causal agitation mechanism, and the company has observed anti-agitation results in multiple clinical studies across several neuropsychiatric disorders. The drug is in Phase Ib/II trial assessing safety, pharmacokinetics, tolerability, and efficacy by administering it twice daily for seven days to patients with opioid withdrawal symptoms.

Get In-Depth Knowledge on Opioid Use Disorder Market Trends and Forecasts with DelveInsight @ Opioid Use Disorder Treatment Market [https://www.delveinsight.com/sample-request/opioid-use-disorder-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Opioid Use Disorder Therapies and Companies

* CAM2038: Braeburn Pharmaceuticals
* BXCL501: BioXcel Therapeutics
* MN-166: MediciNova
* AZD4041: AstraZeneca
* CVL-354: Cerevel Therapeutics, LLC
* INDV-2000: Indivior Inc.
* NYX-783: Aptinyx

Opioid Use Disorder Treatment Market

Although effective therapies are available, only about 1 in 4 patients with opioid use disorder (OUD) receives specialized care. Medication for opioid use disorder (MOUD), considered the "gold standard" of treatment, is an evidence-based approach for managing OUD. While counseling and behavioral therapies are important components of treatment, they are not effective on their own. Medications help treat cravings, alleviate withdrawal symptoms, and prevent opioid euphoria. These medications do not "cure" the disorder but increase safety and minimize withdrawal symptoms, which can lead to relapse or continued drug use. The three FDA-approved medications commonly used for OUD treatment are methadone, buprenorphine, and naltrexone.

Opioid Use Disorder Market Dynamics

The Opioid Use Disorder market dynamics are expected to change significantly in the coming years. Following the United States' recognition and response to its opioid crisis, there has been increased awareness and funding for OUD research and development. Although only a few active compounds have proven effective in treating OUD, their various and innovative formulations have significantly enhanced treatment adherence and reduced relapses. The elimination of the DATA 2000 waiver and the cap on the number of patients a physician can treat with buprenorphine is expected to further transform the OUD market landscape in the US, expanding the use of buprenorphine in treatment. Additionally, upcoming policy reforms are projected to improve patient access to medication for opioid use disorder (MOUD) and its utilization in therapy

Unlock Strategic Insights with DelveInsight's Comprehensive Opioid Use Disorder Market Report @ Opioid Use Disorder Market Drivers and Barriers [https://www.delveinsight.com/sample-request/opioid-use-disorder-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Opioid Use Disorder Market Report

* Coverage- 7MM
* Opioid Use Disorder Companies- Indivior PLC, Alkermes, Orexo AB, Titan Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., Mallinckrodt Pharmaceuticals, BioDelivery Sciences International Inc., Viatris Inc., Pfizer, Inc., Hikma Pharmaceuticals PLC, Camurus, and others
* Opioid Use Disorder Therapies- CAM2038, BXCL501, MN-166, AZD4041, CVL-354, INDV-2000, NYX-783, and others.
* Opioid Use Disorder Therapeutic Assessment: Opioid Use Disorder Current marketed and Opioid Use Disorder Emerging Therapies
* Opioid Use Disorder Market Dynamics: Opioid Use Disorder Market drivers and Opioid Use Disorder Market Barriers

Table of Content

1 Key Insights

2 Report Introduction

3 Opioid Use Disorder (OUD) Market Overview at a Glance

4 Executive Summary of Opioid Use Disorder

5 Key Events

6 Disease Background and Overview

7 Treatment and Management

8 Methodology

9 Epidemiology and Patient Population

10 Patient Journey

11 Marketed Drugs

12 Emerging Drugs

13 Opioid Use Disorder (OUD): Seven Major Market Analysis

14 KOL Views

15 SWOT Analysis

16 Unmet needs

17 Market Access and Reimbursement

18 Appendix

19 DelveInsight Capabilities

20 Disclaimer

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=opioid-use-disorder-market-size-in-the-7mm-was-usd-2000-million-in-2023-estimated-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/case-study/respiratory-domain-conference-coverage



This release was published on openPR.